AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Trump's potential economic policies include tariffs, deregulation, and immigration reforms, which could impact inflation, job ...

Nvidia's Q2 FY2025 results were strong, but Q3 may not exceed forecasts significantly, leading to a potential stock price ...

Lumine Group is focused on acquiring and optimizing TMT software companies. Learn why LMGIF stock is a Hold for now, despite ...

Financial writer recommends holding Johnson Controls due to unstable financials, restructuring uncertainties, and regulatory ...

P/E and EV/Sales ratios signal overvaluation. Learn why MNDY stock is a sell, with decelerating growth and high acquisition ...

Grupo Financiero Galicia is benefiting from a rebound in private sector lending activity in Argentina. Market forecasts see ...

VanEck Fallen Angel High Yield Bond ETF offers a 6.32% SEC yield but has lagged inflation. Learn why ANGL ETF may be less ...

Vale (NYSE:VALE) -3.6% in Monday's trading as UBS downgrades shares to Neutral from Buy with an $11.50 price target, cut from ...

Gold prices retreat as the US Dollar strengthens as hopes of aggressive rate cuts fade. China’s economic slowdown concerns ...

Zevia ( ZVIA) is the top gainer in the beverage sector over the last six weeks, with a 72% rally.

Boeing's preferred stock offers a 5.6% yield with dividends paid quarterly starting January 2025. Read why mandatory ...